This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Pulmonary disease				
Pulmonary fibrosis	IL-25 (IL-17E)	<p>Patient sample and mouse studies suggest inhibiting IL-25 could help treat pulmonary fibrosis. In a mouse model of <i>Schistosoma mansoni</i> egg-induced pulmonary fibrosis, IL-25 knockout mice had lower numbers of profibrotic, IL-13-producing type II innate lymphoid cells and lower levels of IL-13 and fibrosis than wild-type mice. In tissue samples from patients with idiopathic pulmonary fibrosis (IPF), levels of IL-25, type II innate lymphoid cells and IL-13 were greater than those in tissue samples from patients without fibrotic lesions. Next steps could include testing IL-25 depletion in additional fibrosis models and developing IL-25-specific inhibitors. Amgen Inc., AstraZeneca plc and Kyowa Hakko Kirin Co. Ltd. have brodalumab, an IL-17 receptor (IL17R; IL17RA) antibody, in Phase III testing to treat psoriasis and psoriatic arthritis and Phase II trials to treat asthma.</p> <p>SciBX 7(5); doi:10.1038/scibx.2014.150 Published online Feb. 6, 2014</p>	Patent and licensing status undisclosed	<p>Hams, E. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Dec. 16, 2013; doi:10.1073/pnas.1315854111 Contact: Padraic G. Fallon, Trinity College Dublin, Dublin, Ireland e-mail: pfallon@tcd.ie</p>